ATE369355T1 - Pyrimidinamid derivate und deren verwendung - Google Patents
Pyrimidinamid derivate und deren verwendungInfo
- Publication number
- ATE369355T1 ATE369355T1 AT03750639T AT03750639T ATE369355T1 AT E369355 T1 ATE369355 T1 AT E369355T1 AT 03750639 T AT03750639 T AT 03750639T AT 03750639 T AT03750639 T AT 03750639T AT E369355 T1 ATE369355 T1 AT E369355T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- derivatives
- pyrimidinamide
- benzoylaminophenyl
- pyridyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0222514.2A GB0222514D0 (en) | 2002-09-27 | 2002-09-27 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE369355T1 true ATE369355T1 (de) | 2007-08-15 |
Family
ID=9944917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03750639T ATE369355T1 (de) | 2002-09-27 | 2003-09-26 | Pyrimidinamid derivate und deren verwendung |
Country Status (24)
Country | Link |
---|---|
US (1) | US7655669B2 (de) |
EP (1) | EP1546127B1 (de) |
JP (2) | JP4463685B2 (de) |
KR (2) | KR20070098940A (de) |
CN (1) | CN100404528C (de) |
AT (1) | ATE369355T1 (de) |
AU (1) | AU2003270277B2 (de) |
BR (1) | BR0314797A (de) |
CA (1) | CA2499822C (de) |
DE (1) | DE60315479T2 (de) |
DK (1) | DK1546127T3 (de) |
EC (1) | ECSP055701A (de) |
ES (1) | ES2288615T3 (de) |
GB (1) | GB0222514D0 (de) |
HK (1) | HK1080459A1 (de) |
MX (1) | MXPA05003253A (de) |
NO (1) | NO20051966L (de) |
NZ (1) | NZ538930A (de) |
PL (1) | PL374443A1 (de) |
PT (1) | PT1546127E (de) |
RU (1) | RU2378267C2 (de) |
SI (1) | SI1546127T1 (de) |
WO (1) | WO2004029038A1 (de) |
ZA (1) | ZA200502304B (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0222514D0 (en) * | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
US7232825B2 (en) * | 2003-05-02 | 2007-06-19 | Guoqing P Chen | Phenylaminopyrimidine derivatives and methods of use |
GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
DE10352979A1 (de) * | 2003-11-13 | 2005-06-09 | Merck Patent Gmbh | Pyridopyrimidinone |
TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
WO2006024834A1 (en) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
US7939541B2 (en) | 2004-09-09 | 2011-05-10 | Natco Pharma Limited | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
US8735415B2 (en) | 2004-09-09 | 2014-05-27 | Natco Pharma Limited | Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
MX2007002819A (es) * | 2004-09-09 | 2007-08-14 | Natco Pharma Ltd | Nuevos derivados de fenilaminopirimidina como inhibidores de bcl-abl cinasa. |
CN1939910A (zh) * | 2004-12-31 | 2007-04-04 | 孙飘扬 | 氨基嘧啶类化合物及其盐和其制备方法与药物用途 |
ATE525073T1 (de) | 2005-01-28 | 2011-10-15 | Novartis Ag | Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten |
MY146795A (en) | 2005-06-09 | 2012-09-28 | Novartis Ag | Process for the synthesis of organic compounds |
US20100216791A1 (en) * | 2006-08-17 | 2010-08-26 | Astrazeneca | Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors |
DK2068938T3 (da) | 2006-09-22 | 2011-04-04 | Novartis Ag | Optimering af behandlingen af Philadelphia-positiv leukæmi med ABL-tyrosinkinaseinhibitor imatinib |
CN101622244A (zh) * | 2006-11-03 | 2010-01-06 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
US7550591B2 (en) * | 2007-05-02 | 2009-06-23 | Chemagis Ltd. | Imatinib production process |
EA017269B1 (ru) * | 2007-05-04 | 2012-11-30 | Айрм Ллк | ПРОИЗВОДНЫЕ ПИРИМИДИНА И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-kit И PDGFR |
EP2152688A1 (de) | 2007-05-04 | 2010-02-17 | Irm Llc | Verbindungen und zusammensetzungen als c-kit- und pdgfr-kinasehemmer |
WO2008151183A1 (en) | 2007-06-04 | 2008-12-11 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
US8288540B2 (en) | 2007-08-22 | 2012-10-16 | Irm Llc | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors |
KR101218926B1 (ko) | 2007-08-22 | 2013-01-04 | 아이알엠 엘엘씨 | 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물 |
US8067422B2 (en) | 2008-03-04 | 2011-11-29 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
CA2798143A1 (en) * | 2010-05-11 | 2011-12-15 | Mahesh Kandula | Compound, synthesis, composition and uses thereof |
EP3569598A1 (de) | 2011-11-17 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Inhibitoren der c-jun-n-terminal-kinase (jnk) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3751742T3 (de) | 1986-01-13 | 2002-11-21 | American Cyanamid Co., Wayne | 4,5,6-Substituierte 2-Pyrimidinamine |
US5215989A (en) * | 1989-12-08 | 1993-06-01 | Merck & Co., Inc. | Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents |
TW225528B (de) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
ITMI992711A1 (it) | 1999-12-27 | 2001-06-27 | Novartis Ag | Composti organici |
US7087608B2 (en) | 2000-03-03 | 2006-08-08 | Robert Charles Atkins | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
GB0022438D0 (en) * | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
GB0025820D0 (en) | 2000-10-20 | 2000-12-06 | Novartis Ag | Organic compounds |
CA2446939C (en) | 2001-05-16 | 2005-08-02 | Matthias Stein-Gerlach | Pyridylpyrimidine derivatives as effective compounds against prion diseases |
GB0222514D0 (en) * | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
CN100555083C (zh) | 2003-12-23 | 2009-10-28 | 皇家飞利浦电子股份有限公司 | 用于浸入式光刻的可除去薄膜 |
-
2002
- 2002-09-27 GB GBGB0222514.2A patent/GB0222514D0/en not_active Ceased
-
2003
- 2003-09-26 AU AU2003270277A patent/AU2003270277B2/en not_active Ceased
- 2003-09-26 KR KR1020077019251A patent/KR20070098940A/ko not_active Application Discontinuation
- 2003-09-26 AT AT03750639T patent/ATE369355T1/de not_active IP Right Cessation
- 2003-09-26 JP JP2004539039A patent/JP4463685B2/ja not_active Expired - Fee Related
- 2003-09-26 KR KR1020057005204A patent/KR100876055B1/ko not_active IP Right Cessation
- 2003-09-26 RU RU2005113153/04A patent/RU2378267C2/ru not_active IP Right Cessation
- 2003-09-26 DK DK03750639T patent/DK1546127T3/da active
- 2003-09-26 US US10/528,913 patent/US7655669B2/en not_active Expired - Fee Related
- 2003-09-26 PT PT03750639T patent/PT1546127E/pt unknown
- 2003-09-26 PL PL03374443A patent/PL374443A1/xx not_active Application Discontinuation
- 2003-09-26 SI SI200331014T patent/SI1546127T1/sl unknown
- 2003-09-26 EP EP03750639A patent/EP1546127B1/de not_active Expired - Lifetime
- 2003-09-26 WO PCT/EP2003/010724 patent/WO2004029038A1/en active IP Right Grant
- 2003-09-26 CN CNB038232138A patent/CN100404528C/zh not_active Expired - Fee Related
- 2003-09-26 NZ NZ538930A patent/NZ538930A/en unknown
- 2003-09-26 MX MXPA05003253A patent/MXPA05003253A/es active IP Right Grant
- 2003-09-26 CA CA2499822A patent/CA2499822C/en not_active Expired - Fee Related
- 2003-09-26 DE DE60315479T patent/DE60315479T2/de not_active Expired - Lifetime
- 2003-09-26 ES ES03750639T patent/ES2288615T3/es not_active Expired - Lifetime
- 2003-09-26 BR BR0314797-5A patent/BR0314797A/pt not_active IP Right Cessation
-
2005
- 2005-03-18 ZA ZA200502304A patent/ZA200502304B/en unknown
- 2005-03-23 EC EC2005005701A patent/ECSP055701A/es unknown
- 2005-04-22 NO NO20051966A patent/NO20051966L/no not_active Application Discontinuation
- 2005-12-23 HK HK05111972A patent/HK1080459A1/xx not_active IP Right Cessation
-
2009
- 2009-10-09 JP JP2009235252A patent/JP5178681B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60315479D1 (de) | Pyrimidinamid derivate und deren verwendung | |
EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
WO2004005281A8 (en) | Inhibitors of tyrosine kinases | |
TW200615266A (en) | Organic compounds | |
ATE538794T1 (de) | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer | |
ATE408601T1 (de) | Fredericamycin-derivate | |
ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
BR0113838A (pt) | Derivados de n-fenil-2-pirimidina-amina | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
DE602004032522D1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
ATE233754T1 (de) | Diphenyl-piperidin derivate | |
DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung | |
EE200100520A (et) | N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena | |
NO20030021D0 (no) | Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV | |
DE60327249D1 (de) | Anthranilsäureamide und ihre pharmazeutische verwendung | |
TW200626591A (en) | Amide derivatives, their manufacture and use as pharmaceutical agents | |
DE50304524D1 (de) | Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole | |
ATE293107T1 (de) | Luminacine analoge und deren verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1546127 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |